FirstImpact: Recent developments in triple-negative and adjuvant HR+/HER2- breast cancer

Exclusive to FirstWord Pharma PLUS subscribers - register for our live presentation next week of findings from a survey of 120 oncologists evaluating how new clinical data will shape the treatment of triple-negative and adjuvant HR+/HER2- breast cancer.

_______________

Triple-negative breast cancer (TNBC) represents approximately 20% of all breast cancer cases. Until recently no targeted therapy option was available for this disease and patients relied on chemotherapy to delay its progression.

Approval of Roche's Tecentriq last year has transformed the treatment landscape for PD-L1-positive TNBC patients with advanced disease and it is has rapidly become the standard-of-care first-line therapy. Competition is set to imminently emerge from another immunotherapy: Merck & Co.'s Keytruda. Furthermore, recently presented data illustrates the promise of these two immunotherapies as neo-adjuvant TNBC treatments.

Elsewhere, the antibody-drug conjugate (ADC) therapy Trodelvy, developed by Immunomedics, has demonstrated highly impressive data in third-line TNBC, prompting Gilead Sciences to recently acquire Immunomedics for $21 billion. The hope is that Trodelvy can demonstrate similarly compelling data in earlier-line settings and in the larger cohort of patients with HR-positive, HER2-negative breast cancer.

The treatment paradigm for HR-positive, HER2-negative breast cancer has evolved considerably in recent years thanks to the launch and rapid adoption of CDK4/6 inhibitors such as Pfizer's Ibrance and Eli Lilly's Verzenio.

Success of these agents for the treatment of metastatic disease has prompted evaluation in the adjuvant setting where new data readouts have delivered something of a head-scratcher; positive results for Verzenio and negative data for Ibrance.

_______________

To help FirstWord Pharma PLUS subscribers better understand how recent developments will impact the use of these therapies we will be presenting findings from a survey of 120 oncologists at an exclusive FW Live: FirstImpact event next Thursday (October 29). Please click here to register if you are a FirstWord Pharma Plus user or here to find out how to become a FirstWord Pharma PLUS subscriber.

FirstImpact is the newest addition to our Insight, Analysis and Views content offering FirstWord Pharma PLUS subscribers access each year to up to a dozen live events where our analysts present analysis of breakthrough clinical data based on physician surveys. It changes the game in pharmaceutical market news, providing industry professionals with superior analyses of the most important and disruptive clinical catalysts from the unique vantage point of prescribers.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more Physician Views articles, click here.